Form 483

Raritan Pharmaceuticals, Inc. Form 483, 2012-08-21

FDA issued a Form 483 to Raritan Pharmaceuticals, Inc. on 2012-08-21 with 4 public-safe observations.

483· Form 483 issued4 observations

Raritan Pharmaceuticals, Inc. · East Brunswick, United States · Issued August 21, 2012

Overview

  • 4 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

21 Aug 2012
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Maria Estrella

21 Aug 2012
21 CFR 211.165(e)

Test methods

Cited by Maria Estrella

21 Aug 2012
21 CFR 211.166(a)(3)

Valid stability test methods

Cited by Maria Estrella

21 Aug 2012
21 CFR 211.194(a)(2)

Statement of methods and data

Cited by Maria Estrella

Inspected site

RPRaritan Pharmaceuticals, Inc.East Brunswick, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.165(e)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)(3)Cited across public-safe Form 483 observations1x
21 CFR 211.194(a)(2)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 4 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere